Rationale and Trial Design of DAWNA‐FES Trial: Single‐Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [ 18 F]FES PET/CT in Patients With HR+/HER2− Advanced Breast Cancer
Cancer Innovation · 2026-06 · 5 (3)
DOI: 10.1002/cai2.70058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Innovation, online erschienen am 30.04.2026. Verfasst von Ru Yao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Peking Union Medical College Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Cyclin‐dependent kinase 4/6 (CDK4/6) inhibitors have become a cornerstone in the first‐line management of hormone receptor‐positive, human epidermal growth factor receptor 2‐negative (HR+/HER2−) advanced breast cancer. Despite their clinical efficacy, most patients eventually experience disease progression, and optimal treatment strategies following CDK4/6 inhibitor resistance remain unclear. Emerging evidence suggests that switching endocrine therapy (ET) while continuing cyclin inhibition may provide additional clinical benefit. Dalpiciclib, a selective CDK4/6 inhibitor, in combination with physician‐selected ET, represents a potential option in this setting. Concurrently, 16α‐[ 18 F]fluoro‐17β‐estradiol ([ 18 F]FES) PET/CT, a novel imaging modality targeting estrogen receptors (ER), enables non‐invasive, whole‐body assessment of ER expression in metastatic lesions, offering a personalized approach to treatment selection.
Methods
This is a prospective, single‐center, single‐arm Phase II clinical trial evaluating the efficacy and safety of dalpiciclib plus ET in HR+/HER2− advanced breast cancer patients who progressed on prior CDK4/6 inhibitor therapy. Forty eligible patients with confirmed metastases and at least one [ 18 F]FES‐positive lesion will be enrolled. Participants will receive dalpiciclib combined with ET as determined by the treating physician. The primary endpoint is progression‐free survival (PFS). Secondary endpoints include objective response rate (ORR), disease control rate (DCR), and overall survival (OS).
Discussion
Beyond evaluating efficacy, this single‐center phase II trial will provide practical insight into the feasibility of [ 18 F]FES PET/CT‐guided patient selection, including standardized imaging workflows and multidisciplinary implementation in routine clinical research. Positive outcomes may support a personalized, imaging‐guided strategy to prolong disease control after prior CDK4/6 inhibitor progression. Ethical Approval and Trial Registration Approved by the Ethics Committee of Peking Union Medical College Hospital (Approval number: K3629); registered at ClinicalTrials. gov (NCT05613270).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Surgery, Peking Union Medical College Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China.
- Department of Nuclear Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China.
Zitieren
APA
Yao, R., Qu, Y., Hao, Z., Xu, Y., Zhang, J., Lian, J., Gao, L., Shen, S., Mao, F., Pan, B., Sun, Q., Huo, L., & Zhou, Y. (2026). Rationale and Trial Design of DAWNA‐FES Trial: Single‐Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [ 18 F]FES PET/CT in Patients With HR+/HER2− Advanced Breast Cancer. Cancer Innovation, 5(3). https://doi.org/10.1002/cai2.70058
Vancouver
Yao R, Qu Y, Hao Z, Xu Y, Zhang J, Lian J, et al. Rationale and Trial Design of DAWNA‐FES Trial: Single‐Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [ 18 F]FES PET/CT in Patients With HR+/HER2− Advanced Breast Cancer. Cancer Innovation. 2026;5(3). doi:10.1002/cai2.70058
BibTeX
@article{Yao2026,
author = {Yao, Ru and Qu, Yang and Hao, Zhixin and Xu, Ying and Zhang, Jiahui and Lian, Jie and Gao, Lu and Shen, Songjie and Mao, Feng and Pan, Bo and Sun, Qiang and Huo, Li and Zhou, Yidong},
title = {Rationale and Trial Design of DAWNA‐FES Trial: Single‐Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [ 18 F]FES PET/CT in Patients With HR+/HER2− Advanced Breast Cancer},
journal = {Cancer Innovation},
year = {2026},
volume = {5},
number = {3},
doi = {10.1002/cai2.70058}
}
EUVIMED